![Frank Mühlenbeck](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Frank Mühlenbeck
Private Equity Investor chez
LBBW Venture Capital GmbH
Profil
Dr. Frank Mühlenbeck is a Managing Director at LBBW Venture Capital GmbH.
Dr. Mühlenbeck was previously employed as a Managing Director by EMBL Ventures GmbH, an Independent Director by ConforMIS, Inc., a Partner by aeris CAPITAL AG (Venture Capital), a Partner by firstVentury Equity GmbH, a Member-Supervisory Board by Affimed NV, a Member-Supervisory Board by Affimed Therapeutics AG, a Principal by Boehringer Ingelheim GmbH, a Chairman-Supervisory Board by Curetis GmbH, a Member-Supervisory Board by Curetis NV, a Principal by Mitsubishi Research Institute, Inc., a Chairman by Sensovation AG, and a Principal by Steinbeis Europa Zentrum.
He also served on the board at Sonetik AG, Barnev, Inc., Solstice Biologics LLC and Sonetik AG.
He received his doctorate degree from Universität Stuttgart.
Postes actifs de Frank Mühlenbeck
| Sociétés | Poste | Début |
|---|---|---|
LBBW Venture Capital GmbH
 LBBW Venture Capital GmbH Investment ManagersFinance LBBW Venture Capital invests in companies located in DACH region. The firm targets companies operating in the fields of disruptive information technology, life sciences, software, digital formation and fintech. It provides financing for seed and early stage capital requirements with an investment size up to EUR 3 million. | Private Equity Investor | 01/10/2023 |
Anciens postes connus de Frank Mühlenbeck
| Sociétés | Poste | Fin |
|---|---|---|
EMBL Ventures GmbH
 EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures is a hands-on, long-term manager which invests in disruptive biology and life-science related products and technologies with global potential, including therapeutics, target validation and drug design, technology platforms, medical devices and diagnostics developed at the EMBL, from EMBL alumni and from non-EMBL third parties. The firm seeks to invest in entrepreneurial management teams with: a combination of relevant technical expertise, drive, business sense and a down-to-earth attitude; ownership of a proprietary core or platform technology generating a proprietary position or clear competitive advantage in a defined market sector and a solution for a problem with a significant advantage in a market of substantial size and the chance to achieve a leading, sustainable market position. EMBL Ventures typically acts as the lead or co-lead investor for initial financing and also participates in follow-up financing. They partner with their investee companies, taking a seat on the board of directors. To maximize the intrinsic value of a technology or product, the firm's investment strategy targets one of the main value inflection points, typically the transition from early development or conceptual stage up to proof of concept. | Private Equity Investor | 30/10/2023 |
| CURETIS N.V. | Directeur/Membre du Conseil | 16/06/2016 |
Solstice Biologics LLC
 Solstice Biologics LLC Pharmaceuticals: MajorHealth Technology Develops cell-permeable RNAi pro-drugs | Directeur/Membre du Conseil | 01/10/2015 |
Affimed NV Niederlassung Deutschland
 Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Discovers and develops antibody-based therapeutic drugs | Directeur/Membre du Conseil | 01/10/2015 |
Calibrium Private Investments GmbH
 Calibrium Private Investments GmbH Investment ManagersFinance Calibrium Private Invt invests in small and middle market companies located in the United States, Austria, Germany and Switzerland. The firm targets companies operating in the fields of healthcare, consumer products, information technology, energy and business services. It provides financing for early and buyout transactions. | Private Equity Investor | 01/10/2015 |
Formation de Frank Mühlenbeck
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
22
Relations au 1er degré
17
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 17 |
|---|---|
Boehringer Ingelheim GmbH
 Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Manufactures and wholesales animal health & pharmaceutical products | Health Technology |
ConforMIS, Inc.
 ConforMIS, Inc. Medical SpecialtiesHealth Technology Manufactures and sells joint replacement implants | Health Technology |
Solstice Biologics LLC
Solstice Biologics LLC Pharmaceuticals: MajorHealth Technology Develops cell-permeable RNAi pro-drugs | Health Technology |
Affimed NV
 Affimed NV Pharmaceuticals: MajorHealth Technology Discovers and develops antibody-based therapeutic drugs | Health Technology |
Mitsubishi Research Institute, Inc.
 Mitsubishi Research Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Provides technology consulting and information technology services | Commercial Services |
EMBL Ventures GmbH
EMBL Ventures GmbH Investment ManagersFinance EMBL Ventures is a hands-on, long-term manager which invests in disruptive biology and life-science related products and technologies with global potential, including therapeutics, target validation and drug design, technology platforms, medical devices and diagnostics developed at the EMBL, from EMBL alumni and from non-EMBL third parties. The firm seeks to invest in entrepreneurial management teams with: a combination of relevant technical expertise, drive, business sense and a down-to-earth attitude; ownership of a proprietary core or platform technology generating a proprietary position or clear competitive advantage in a defined market sector and a solution for a problem with a significant advantage in a market of substantial size and the chance to achieve a leading, sustainable market position. EMBL Ventures typically acts as the lead or co-lead investor for initial financing and also participates in follow-up financing. They partner with their investee companies, taking a seat on the board of directors. To maximize the intrinsic value of a technology or product, the firm's investment strategy targets one of the main value inflection points, typically the transition from early development or conceptual stage up to proof of concept. | Finance |
Affimed NV Niederlassung Deutschland
Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Discovers and develops antibody-based therapeutic drugs | Health Technology |
Barnev, Inc.
 Barnev, Inc. Information Technology ServicesTechnology Services Develops, manufactures and distributes labor monitoring systems | Technology Services |
Universität Stuttgart
 Universität Stuttgart Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sensovation AG
 Sensovation AG Electronic Equipment/InstrumentsElectronic Technology Manufactures and markets scientific imaging instrumentation technologies | Electronic Technology |
firstVentury Equity GmbH
 firstVentury Equity GmbH Investment ManagersFinance Acts as an alternative investment manager | Finance |
LBBW Venture Capital GmbH
LBBW Venture Capital GmbH Investment ManagersFinance LBBW Venture Capital invests in companies located in DACH region. The firm targets companies operating in the fields of disruptive information technology, life sciences, software, digital formation and fintech. It provides financing for seed and early stage capital requirements with an investment size up to EUR 3 million. | Finance |
Calibrium Private Investments GmbH
Calibrium Private Investments GmbH Investment ManagersFinance Calibrium Private Invt invests in small and middle market companies located in the United States, Austria, Germany and Switzerland. The firm targets companies operating in the fields of healthcare, consumer products, information technology, energy and business services. It provides financing for early and buyout transactions. | Finance |
Curetis GmbH
 Curetis GmbH Medical SpecialtiesHealth Technology Develops miniaturized and integrated molecular diagnostic solutions | Health Technology |
Sonetik AG
 Sonetik AG Medical SpecialtiesHealth Technology Manufactures and markets hearing aid solutions | Health Technology |
Steinbeis Europa Zentrum | |
Curetis NV
 Curetis NV Medical/Nursing ServicesHealth Services Develops miniaturized and integrated molecular diagnostic solutions | Health Services |
